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The purpose of this paper is neither to affirm nor 
deny the usefulness of sulfanilamide. Instead, this is 
a report of an effort to learn something of the "mode of 
action" of sulfanilamide, since so little actually is 
known. 
Various and varying reports of the bacteriostatic 
effect of sulfanilamide have left the impression that 
much, perhaps all, of the principal activity of this drug 
is as yet unknown, especially since there is such a wide 
discrepancy between the observed effects clinically and 
the relatively feeble germ-killing powers of the drug in 
the test tube. 
A brief resume of the history, chemistry, pharmac-
ology, toxicology, and therapeutics have been included 
to serve as a brief review. Toxic manifestations have 
merely been mentioned for if the drug is to be used in-
telligently, it follows that more must be known of its 
mechanisms within the body. Therefore more experimen-
tation and test for reactions other than germ killing 
power are quite in order to ascertain the drugs toxic 
properties. 
INTRODUCTION 
Sulfanilamide, and to a lesser degree some of its 
derivatives, constitute the greatest advance in chemo-
therapy since the discovery of salvarsan ( 92). In the 
subsequent annals of medical history it may indeed rival 
this product as an alleviator of disease and human suf-
fering. 
As the reader has probably already observed, over-
en thusiasm inevitably follows the discovery of a new 
therapeutic agent, particularly that discovery which 
tends to be startling or which carries with it a dram-
atic appeal. Davis (33) describes such enthusiasm by 
plotting a curve, in which he lists the various phases 
through which the drug passes after over-enthusiasm, in 
varying degree but in definite aequence, come publicity, 
commercial exploitation, incompetence and abuse, followed 
by poor results, recognition of defect• and dangers, fear, 
decreased use and over-correction; until, finally such 
merits as may exist become recognized in their t••e light 
and the new therapeutic agent reaches stability at its 
proper level of usefulness (Fig. I). 
Mercurochrome, mandelic acid, fever therapy and 
many other therapeutic measures have had their fling 
and each their appraisal. The most recent conspicuous 
example is the magic medicine sulfanilamide, certainly 
.r'· 
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a drug of moat unusual merit, although falling somewhat 
short of enabling the internist to dispense with history 
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Fig. I. Trial and Appraisal: The reaction 
of the medical profession toward anything new. 
Considerable discussion concerning the "mode of ac-
tion" of sulfanilamide has arisen during the past months 
and years; but it would be wiser first to consider na-
tures attempts to rid the body of its infection with-
out the aid of therapeutic measures. Rous (III) stresses 
that fact in his article "The Doctor and Nature", in which 
he states that the 4octor has always deemed himself eager 
to listen to nature and to carry out her commands. He 
has always spoken of aiding her, of not offending her, 
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of letting her take her course, time and again he has 
conceded that "Nature is the best Physician" an admission 
not the less wise because the fact has so often been 
staringly evident. The doctor has found that while he 
can hurry Nature or impede her, help her, or narrow her 
field of activities (as when the surgeon takes out an 
organ), he can not change her ways, much less flout them. 
He sees, too, that in many respects he is already wiser 
than the body. Frequently now he can go nature one bet-
ter in healing the sick through exploitation of the re-
sources that she provides, as for example, the hormones. 
In a more indirect manner, the resources of mental achieve-
ments by chemical synthesis---sulfanilamide. Who was it 
said that discovery results from chance? The prepared 
mind of nowdays makes its own chances. It is not content 
with what comes its way, but devises occasions, goes out 
to find worlds of which there may be no token. So it is 
the doctor who sets forth to discover. Domgk (35 ), by 
a systematic method of experimentation found that pron-
tosil was effective in preventing death of a dog, if ad-
ministered within twenty-four hours after infection with 
streptococcus. At that time, however, he was unable to 
give a definite theory as to its mode of action. 
-3-
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The doctor invents instruments and technics with 
complete assurance that they will disclose things worth 
while, though he may not know what. Knowledge has come 
to him in the past mostly through experimentation---which 
began with the first dose ever given to a sick man; and 
now he is determined to ma.ke the experimental method yield 
everything that is in it. This decision is not peculiar 
to him: as you well know, a furor for experimentation 
has seized of late upon all thinking humanity. It has 
been applied even to the most delicate and lovely of human 
relationships not without casualties at times, as one may 
remark in passing. However the sick man is none the worse 
because the doctor as an experimenter has found that the 
major laws which rule in the body of animals rule with a 
striking particularity in the human organism as well: and 
from the study of diseased, lower creatures he has learned 
about man (III). This has been especially true, in the 
attempt that has been made to determine the "mode of ac-
tion" of sulfanilamide. Much difficulty has been encount-
ered because of its change in reaction, when in vivo as 
compared to in vitro. 
Many times a drug is used before the doctor or any 
one else really knows what reaction might be expected. 
-4-
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Three tasks set before every doctor,---to see, to know, 
and to do---are notably difficult: he has to perceive 
disease pl'Ienomena, to understand them, and to cure or 
at least make them tolerable,preventing future instances. 
The difficulty with this task has been that sick and well 
alike have forced the doctor to act before he could know, 
and to assume, for practical purposes, that he knew be-
fore it was possible for him to perceive. Throughout 
countless years people all about the doctor have cried, 
nWhy don't you do something?" At last these things have 
been placed in their proper order. A drug must first 
be accepted by the Council of Pharmacy and Chemistry be-
fore it can be used by the practitioner. In most in-
stances doseage, toxic effects, etc. have been worked 
out before the council accepts the new substance. After 
such experimental data is available the doctor sees where 
next to direct his energies and how to bring them to bear. 
Sulfanilamide and its derivatives present a similar situa-
tion; although sulfanilamide has been officially accepted 
some of its derivatives are still in the experimental stage 
and their therapeutic value questioned. 
-5-
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The history of sulfanilamide as gained from a re-
view of the literature shows that a relatively simple 
compound which was known to organic chemists for 30 years 
eventually found its way into the class of medicinals---
first, as a component of the mo•e complicated azo dyes, 
and eventually as an independent compound. 
The first data on the manufacture of p-aminophenyl-
sulphonamide is given in a paper by Gelmo ( 50 ), publish-
ed in 1908. This paper deals with a purely scientific 
experiment without technical goal. One year later 
H6erlein (63) prepared together with Dressel and Kothe, 
the first azo dyestuffs with sulphonamide by substituting 
sulphonamide groups. These products were used for tex-
tile purposes and were distinguished by being more fast 
to washing and fulling than the corresponding sulphon-
amide--free products. Allport ( 4 ) likewise gives Gelmo 
credit for being the first to prepare p-aminobenzensul-
phonamide. H6erlein, while working with Dressel and 
Kothe on the azo textile dyes, found that one possessed 
a limited therapeutic action against mouse septicemia 
caused by hemolytic streptococci ( 9~. This compound 
-6-
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had the following formula: 
C~Hs> ~1 0 NV N=tf S01HH2. 
NH2.C'7_C IOI/ C/I;. 
As early as 1913 Eisenberg ( 6:5} observed that cer-
tain azo dyes possessed considerable bactericidal action 
in vitro and considered the possibility of the applica-
ti on Of chyrsoidin .H.,NQ N= No 
NII,. 
to therapeutics. 
He, however, soon convinced himself that the product 
mentioned had no therapeutic effect what ever on the in-
fected living animal. 
In 1919,Jacobs and Heidelberger ( 63) tried to in-
crease the bactericidal properties of the quinine mole-
cule by coupling the dihydrocuprein, to azo compounds. 
In the condusion of their paper they make a note to the 
effect that numerous of the new compounds show bacteri-
cidal properties in vitro (like the azo dyestuff of 
Eisenberg}. However Herlein (63 ) has found in subse-
quent experiments that the azo dyestuff made from p-
aminophenylsulphona.mide and dihydrocuprein does not 
possess sufficient efficiency against streptococci to 
warrant its use. for therapeutic purposes. 
llietszch.and Klarer in 1932 (II3) synthesized an 
azo dye for the dye industry and obtained the patent, 
-7-
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in Germany under the name of prontosil. This compound 
was a red crystalline powder, which is 0.25 per cent 
soluble in cold water and has a melting point of 247 
to 251 O. During the same year, DomagM ( 36) working 
with Mietszch and Klarer discovered the efficacy of these 
azo dyes in streptococcic septicemia of mice, and the 
chemists synthesized a new drug by adding an azo-naph-
thalene ring and including the sulfanilamide group. 
They patented this compound which was known as strep-
tozon, prontosil s, prontosil red, and prontoeil solution. 
It is the d~soduim salt of 4 sulfonamide-benzene 2 azo 
7 acetylamino 1 hydroxy-naphthalene 3:6 disulfonic acid 
and is four percent soluble in cold water. 
H,_Na,.sQ N ~tfcol(ff(OC.HJ 
,,._el 'SO,, Mil,. 
Further investigation by Domagk (35) resulted in the 
development of 2, 4-diaminoazobenzene-4-sulfonamide 
hydrochloride, which was patented by Mietzsah and Klarer 
in 1935 ( ) . 
This compound, a brick-red powder was highly efficacious 
in experimental infections of a streptococcal nature but 




Early in 1935 Domagk: ( 35) in Germany announced the 
startling chemotherapeutic success with the administra-
tion of a substance to mice innoculated with hemolytic 
streptococcus from a human source. Cultures injected 
into the peritoneum of untreated controls killed the 
animals in 24 to 48 hours. With doses of 1/10 to 1/50 
of the tolerated dose of prontosil most of the treated 
animals recovered in from 3 to 5 days, and after recovery 
no pathological changes were found in the tissues, such 
as were present in the controls. To Domagk:,right-fully 
belongs the credit for the discovery of prontosil as a 
chemotherapeutic agent for use in bacterial infections. 
Many papers on the clinical use of prontosil began making 
their appearance after Domagk: made his report in 1935. 
Colebrook made his· first reports in England during 1936. 
J. & Mme. Trefoull, Nitti and Bovet ( 43) of France~ 
in a study of azo compounds (in 1935) found that those 
in which the sulfonamide group was not attached to a 
benzene nucleus was inactive. Therefore the azo linkage 
was unnecessary a.nd the much simpler compound, p-amino-
benzensulphonamide was equally effective. Mouse pro-
tection experiments conducted with p-aminobenzenesul-
fone.mide hydrochloride verified this assumption and 
-~ 
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,roved conclusively that the azo linkage was unnecessary. 
During the International Congress of Microbiologists 
in London at the end of July, 1936, the new class of med-
icaments against streptococci was not the subject of a 
lecture or demonstration, but it was the topic of personal 
corn.rnunication and in this way Dr. Long, and Miss E. Bliss 
of Johns Hopkin Hospital in Baltimore were informed at 
that time by Dr. Colebrook of the success of his investi-
gation (63 ). Dr. Long's appreciation of the potenti-
alities of the new therapeutic agents induced him on his 
return to the United States, to study carefully two pro-
ducts from this series, namely prontosil and prontylin. 
It was Bliss and Long (74) who in 1937 concluded that, 
prontosil solution, which had been subjected to reduc-
tion with cysteine hydrochloride, inhibits the growth 
of beta hemolytic streptococcus in vitro. Fuller (48 ) 
states that a considerable amount of sulfanilamide is 
excreted when prontosil is given by mouth or by injec-
tion and he feels that the therapeutic action of pron-
tosil is due to the sulfanilamide derived from it by re-
duction in the body. 
Since the introduction of these drugs into this 
country by Long & Bliss (1936) much experimental work 
-10-
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has been done, but there is as yet much controversy as 




P-aminobenzenesulphonamide was first described by 
Gelmo (50) in a general study of the sulphonamides of 
sulphanilic acid. He prepared it by hydrolyzing the 
amide of acetylsulphanilic acid with boiling diluted 
hydrochloric acid and decomposing the resulting hydro•. 
chloride of p-a.~inobenzenesulphonamide with the equivo-
lent quantity of sodium hydroxide. The amino-acetyl-
sulphanilic acid was prepared from N-acetylsulphanilic 
acid chloride which can be produced by the action of 
phosphorus pentachloride on sodium N-acetylsulphanilic. 
acid dhloride which can be produced by the action of 
phosphorus pentachloride on sodium N-acetylsulphanilate. 
This was described as a 'White crystalline substance which 
melted at 163 C.: ~s~NH,.. 
But Allport ( 4 ) , from a study of the compound, suggested 
~he following specifications for medicinal sulfanilamide: 
Melting point: 165.0-166.5 c. 
Reaction (0.5 per cent sol'u): PH 5.8-6.l 
Ash: 
Arsenic: 
HeaV'J metals (as lead): 
Sulfate and Chloride: 
-12-
Less than 0.02 per cent 
Less than lpart per million 
Less than 5 parts per million 
Trace 
CBElUSTRY 
Assay by total sulfur: 99.5-100.5 percent sulfanilamide. 
In 1937 the Council on Pharmacy and Chemistry of the 
American Medical Association (30 ) (3I ) formally adopted 
the non-proprietary name "sulfanilamide" for para-amin-
obenzenesulfonamide. Although the Council preferred a 
shorter term, a representative of the firm, which was 
the first to submit a non-proprietary product to the 
Council, pointed out that "sulfanilamide" denoted the 
composition and that the name was being used abroad. 
Other interested firms agreed. The Council (30) ac-
cepted the following specifications as conforming for 
admission to New and lfonofficial Remedies: 
1.!l:elting Point: 
H.eaction: 





Not less than 165 or more 
than 167 C. 
Neutral to litnru.s 
1.60 
Negative ( 0. 5 gm. sample) 
Negative (o. 5 gm. sample) 
Negative (0. 5 gm. sample) 
Not more than 0.05 percent 
Arsenic and heavy metals: Sample shall pass test for 
arsenic and heavy metals 
( u. s. P. method) 
lloisture: Less than one per cent. 
Carbonization in concentra- None 
ted sulfuric acid. at 100 C: 
-13-
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Total Sulfur (theoretical 18.6): Not less than 18.3 or 
more than 18.9 per cent. 
Various trade names have been given to p-aminoben-
zensulphonamide and as a result considerable confusion 
is unavoidable.. In order to clarify this point some of 
the more common preparations with their manufacturers 
are given below ( 43 ) : 
Prontosil Album----Bayer Products Ltd. 
Sulphonamide-P-----Allen & Hanbury Ltd. 
Sulphonamide-P-----Burroughs, Wellcome & Co. 
Sulphonamide-P-----British Drug Houses Ltd. 
Colsulanyde---------Crook'a Laboratories 
P. A. B. 8.--------C.J.Rewlett & Son Ltd. 
Prontylin----------Winthrop Chem. Co. Inc. 
Streptocide--------Evans Sons Lescher & Webb Ltd. 
Sulfamidyl---------Abotts Lab. 
Sulfanilamide------Squibbs & Sons 
Sulphanilamide-----Boots Pure Drug Co. Ltd. 
Sulfanilamide------Council of Pharm. & Chem. 
The extensive use of sulfonamide derivatives ex~ 
perimentally and clinically has made it necessary to de-
velop certain tests to determine their concentration in 
the body fluid. Marshall ( 83) devised a method for the 
analysis of sulfanilamide of the blood and urine (as well 
-14-
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as certain other body fluids). It is based on diazotiz-
ation of the aminabenzenesulfonamide with nitrous acid, 
and coupling the resulting diazo compound in acid solu-
tion with di-methyl and naphthylamine to produce a pur-
plish red azo dye v1hich can easily be estimated by color-
imeteric comparison. This reaction depends upon an amino 
group substituted in the benzene ring and will estimate 
any compound to which the sulfanilamide is changed in the 
organism and in v;hich the amino group is intact. This 
color reaction is extremely delicate, being detectable 
in a solution of sulfonamide of 1:20,000,000. Numerous 
attempts to correlate therapeutic efficacy with the chem-
ical structure of sulfonamide compounds have proved dis-
couraging. 
Most authorities now feel that it is necessary to 
have the sulfonamide group in the "para" position to 
provide for streptococcal efficiency ( 63). The azo 
structure does not seem to provide the azo compounds 
with their therapeutic efficacy. The necessity of having 
the sulfonamide group in para-position as provision for 
streptococcic efficiency as a matter of course induced 
the study of other substances ( 63), outside of the azo 
series, which have the sulphonamide group in para-posi-
-15-
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tion to other substituents. The experiments were there-
fore logically extended to the sulphonamide compounds 
of benzol, naphthalene, quinolene, and acridine series 
as well as derivatives of diphenyl ether, diphenylamine, 
azo methene compounds and others. In the course of these 
experiments it was found that even simple benzol deriva-
tives with a sulfonamide group in the para-position to 
an amino group were effective against streptococcus. 
This simplest substance is 4-aminophenylsulphonamide: 
(sulfanilamide) 
The term now officially accepted by the Council of Phar-
macy and Chemistry of the American Medical Association 
( 63). 
Although investigations in 1937 seemed to point 
strongly to the para-linked sulfonamide group as the 
seat of antibacterical activity, those of more recent 
date appear to connect this activity with the para-linked 
sulfur ( 92 ) • 
The search for new and more efficacious therapeutic 
agents has resulted in the development of numerous sul-
fonamide or closely related compounds. Very little is 
known of their properties but a brief discussion of the 




Pharmacology is the sum of knowledge regarding 
drugs; the term is usually restricted to the study of 
the action of drugs (37 ). In this chapter however 
the 0mode of action" is not discussed; it has been set 
aside as a separate chapter. 
Sulfanilamide, like prontosil, acts as a relatively 
indifferent substance on both the body functions and 
structures, particularly after single doses ( I04). 
Therapeusis with sulfanilamide has been accomplished 
by the oral, subcutaneous, intramuscu&ar, intravenous, 
intrathecal, 1ntrapleural and rectal routes and some 
also by topical application (92 ). The oral method is 
the more desirable because of its simplicity and 
practicability. Unless contra-indicated by the condition 
of the patient, it is by far the most desirable. In 
two series of experiments by Branham and Rosenthal {I9) 
the subcutaneous route was found to be more effective. 
This may, however, have been caused by the rapid absorp-
tion. (see figure 12 ) The ease with which the drug may 
be taken orally seems to offset the subcutaneous method, 
provided there are no gastric symptoms. 






the gastro-1ntest1nal tract of the human and circulates 







___ s ...,.t. (,,,.,,,) 
Fig: .:2 Comparison of oral and subcutaneous 
therap7 with sulfan1la.m1de in men1ngococcus 
infection in mtce. I gram per •110 in each 
case, orally (stomach tube) suspended in 
acacia. s.c. 1n oil--one dose only. 
Marshall and his associates found that 1n the human 
subject after a s1ng1• dose of 60 grains, the maxi-
mum concentration in the blood would be reached in 
from I to 4 hours, the average being about 2 hours. 
Anderson ( 5) states that sulfan1lam1de soon reaches 
all parts of the body, regardless of the method used 
for its administration. Its distribution seems to be 
governed chiefly by the water and fluid content of 
the tissues. Marshall ( 81 ) found only a small amount 
of the absorbed drug present in the blood stream. 
Large amoun"tts were evidently taken up by the tissues. 
-18-
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To investigate this point, a study was made on the dog. 
The drug was found present in all tissues of the body 
with the exception of bone and fat, in about the same 
concentration as in the blood. That this holds also 
for man has been shown by examining the spinal fluid 
and blooa of an essentially normal individual as well 
as one during treatment with the drug. This ready 
diffus1b111ty and equal distribution is extremely 
important in making sulfanilamide a successful chemo-
therapeutic agent. 
Stewart (II8) found that after sulfan1lam1de is 
administered intravenously in the normal rabbit, it 
changes in form. (becomes acetylated). Immediately the 
question arose, where was the sulfanilamide being 
acetylated. This was soon determined by a process of 
elimination. First the kidneys were eliminated by 
performing a nephrectomy---the acetylation continued. 
Next splenectomy and complete removeal of the gastro-
intestinal tract, but yet the acetylated form of 
sulf anilamide could be found in the blood. Finally 
the liver was removed, and the acetyl form was fowid 
absent. It was therefore believed that acetylation 
took place in the liver. Sulfan11am1de has been found 
in the liver ( 56) and acetylation was found·,tio be 
-I9-
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dependent upon aerobic respiration. 
Klein ( 68) presents this schematic representation 
of acetylation of sulfanilamide by the rabbit liver: 
lactate---a--.pyruvate--b-..a.cetate + sulfanil-
1 b amide 
I I • • acetaldehyde l 
acetly-
sulf anilamide 
in which (a) is inhibited by anaerobiosis, thus limit-
ing anaerobic acetylation and (b) is oxidation or 
dismutation. The conjugation (c) of acetate and sulf-
anilamide occurs only in the intact liver cell, is 
not reversible, is inhibited by high concentration of 
iodo-acetamide and arsenous oxide, is only slightly 
inhibited by anaerobioeis and varies greatly in 
animals of the same species. It was impossible to 
demonstrate the presence of an enzyme, which might 
account for the coupling process found in acetylation. 
Generally the process is limited by the rate of pro-
duction of acetate by the tissues and may be increased 
by the addition of acetate or those substances which 
may yield acetate in the course of metabolism. 
Sulfanilamide is almost wholly excreted by the 
kidney, the normal filtering it off within twenty-
four hours ( 82). The damaged kidney will hold it back 
and accumulation occurs. In such instances the coneen-
-20-
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trat1on in the blood may rise rapidly, with result-
ant toxic maaifestations. It is important, therefore, 
to do frequent sulfanilamide determinations of the 
blood and urine. It 1a excreted very much like urea 
but is reabsorbed by the tubules.to a greater extent 
(SI). Marshall and his colleagues (83 ) claim that . _ 
V0~'-80% of the glomerular f.iltrate is reabsorbed in 
the renal tubules. Sulfanilamide is excreted by the 
human and rabbit 1n the conjugated form; in the dog, 
however, this is not true. The conjugated compound 
does not give the color reaction directly, owing to 
a block of th.a amino group. The para.-aminobenzene-
eulfonamide can be obtained from this compound by 
bydrolysis with dilute hydrochloric acid(93). 
Some authorities believe that sulfanilamide should 
be maintained in the blood in a concentration of IO to 
15 mgm. per cent. Long and Bliss (73 ) however pre-
scribe I gram per 20 pounds for patients weighing up 
' 
to IOO pounds and placed the maximum at 5 gram per day 
in four divided oral doses, six hours apart. 
When bJpadermoclysis was indicated, treatment was 
carried on ~1th an o.8 per cent solution of sulfan11-
am1de. The recommended schedule was IOO c.c. for 
patients of 40 pounds, 200c.c. for those weighing 40 
-21-
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to 80 pounds, 300c.c. for those 80--!20 pounds, and 
400c.o. for all those over I20 pounds. 
Do.Sages have been increased ( 77 ) ; Adul ts--3 to 5 
grams for the initial dose, followed in 6 to 8 hours 
by I.O to I.5 gram repeated every four hours. Children 
likewise were given more and if a concentration of 
less than IO mgm. per cent appears in the blood, more 
sulfanilamide is given. It has been suggested by 
some authors to give larger doses over shorter intervals, 
thereby causing less strain on the bone marrow. Others, 
however, claim that smaller doses are just as effective 
as the large doses and are therefore not indicated. 
If sens1t1vit1es and idiosyncrasies of the patient 
to sulfanilamide, are omitted; one is justified 1n 
giving sufficient amounts of the drug to maintain a 
concentration level of IO to I5 mgm.· percent. Marshall 
( 80,83 ) and Proom <Io5) have devised reliable methods 
for determining the concentration of sulfan11am.1de both 
in the urine and blood. 
Symptoms, which developed following large doses of 
sulfanilamide varied considerably in different individuals 
but those noted most consistently were as follows ( 57): 
" Within thirty minutes after the first dose had been 
taken, vertigo was experienced, and within two hours 
-22-
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hyperventilation, nausea, anorexia, increased thirst 
and cyanos1s were also noted. These symptoms were 
accompanied by drowsiness, irritability, and very 
evident mental confusion involving principally false 
perception of intervals of time, extreme difficulty 
in concentration and slow response to questions. 
Recovery from the subjective symptoms, 1n the normal 
subjects was not complete for forty-eight hours, with 
vertigo, anorexia, and drowsiness persisting through-
out the day following the administration." No effects 
on the blood pressure of anaesthetized cats and dogs 
were noted from as much as o.I7 gram per kilo-gram 
given intravenously ( 5.9 ) • 
Marshall ( 62 ) gave large doses of sulfan1lamide, 
about I gram per kilo., to two dogs daily by mouth for 
a week but could find no consistent change in the red, 
white or differential count. Likew1se,Hawk1ng (59 ), 
after further investigation found no histological 
changes after large doses. In the animals,which died 
from the drug, Hawking found degenrative changes 
(chromatolysis) in the neurones of the anterior column 
of the spinal cord and some in the nerve cells of the 
cortex and mid-brain. Rabbits receiving 0.25 gram 
prontosil per kilogram of body weight for twenty-one 
-23-
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consecutive days presented red, white and platelet 
counts, which ran closely parallel in the treated 
and untreated animals ( 70 } • Necropsy findings 
suggested early bone marrow depression. 
The symptoms suggest that in acute poisoning by 
large doses of sulfanilamide the stress falls ma1n1y 
on the central nervous system, apart from dyspnea 
which is presumable due to the formation of sulfhemo-
globin ( .59. In cats there seems to be a transient 
paralysis of the cerebral cortex for a few hours; 
in rabbits the cortex is only depressed. 
In concluding, it may be pointed out that the 
symptoms described have little significance in human 
jherapy, since they were obtained only by the use of 
very large doses. It has not been possible to trace 
any case of nervous symptoms in a human being attri-
butable to sulfanilamide or allied compounds. 
A review of the literature discloses a remarkable 
number of reports in which mildly unfavorable collat-
eral reactions and:. occaslo!}ally death have accompanied 
the therapeutic use of sulfanilamide compounds. These 
various manifestations, name~ (I}fever (2) acidosis 
(3) cyanosis (4} nausea & vomiting (5} vertigo and 
·(6) various blood ch~n~ea will be discussed in the 
chapter on 11Toxicity 11 • -'24-
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The intelligent use of any drug demands that its 
mode of action shall if possible be understood, since 
special circumstances may a.rise in which such knowledge 
alone can dictate the right course to adopt. 
It is perhaps scarcely necessary to point out that 
the use of these drugs imperatively demands a bacter-
iological as well as a clinical diagaosis. The drug is 
not specific for septicemia, meningitis, or pneumonia 
but :for infections by certain bacteria wherever: situated, 
while on other species it has little or no effect ( 49). 
It interferes in some way with the activities of these 
bacteria in the body, but the question is, how? 
Our knowledge of the ultimate mechanism of sulfanil-
amide 1 s action in vivo is at best rather meager ( 92 ) • 
In attempting to explain the therapeutic effect of the 
red prontos11s and sulfanilamide two theories have been 
dominant ( 62); the one, that this effect was chiefly 
due to a direct action of sulf anilamide upon the 
coccus; the other, that any such action is only,ancill-
ary to the operation of the cellular defense mechanism 
of the body. 
In the discussion of these two theories, I have 
attemptea. to group the lead.ins authorities under the 
-2> .. 
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proper heading. 
Direct Action of Sulf anila.mide upon the Bacteria 
Levad1t1 and Vaisman quoted by Domagk (36) in their 
research came to the conclusion that the encapsulation 
of the streptococcus which took place,norJllally, before 
phagocytism, was hindered or prevented by prontosil. 
Domagk (36) disagreed for he believed that encapsul-
ation should be a preventative stage and not one that 
invites phagocytism. He thought the first phase of the 
chemptherapeutic effect of prontosil was its conjuga-
tion with the infective agent and later stimulated 
phagocytosis. 
J<1ellon and Cooper (83) suggested the possibility 
of virulent organi,... being transformed into their 
non-virulent phases, as a r.esult of prontosil treat-
ment. In order to substantiate this theory, Mellon (91) 
employed immune hoBse-sera prepared from two anoma-
lous dissociants of a hemolytic streptococcus from a 
human case of cellulitis. Patients responding to this 
treatment often show the streptococci in a definite 
transition from tnttr mucoid or matt to intermediate, 
smooth or rough colony forms. 
Hoerlein (6J) thought that the possibil:t~y of 
combating infectious diseases with chemotherapeutic-
-26;;.. 
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ally active substances depended to a large extent 
upon the structure of the pathogenic organism. The 
more highly developed the organism, the more points 
for attack it offers to the action of the chemo-
therapeutic substances. Dr. M.Fischer, quoted by 
Green (52), believes the mode o~ action of sulfani-
am1de is that of a general protoplasmic poison. 
Colebrook ( 2a demonstrated capsule formation 
by the virulent "Richard's" strain of streptococcus 
in the blood with, as well as without prontosil. The 
possibility that cocci in the treated animals might 
cease to elaborate certain toxic products which may 
be directly responsible for death was considered but 
nothing in its sup•t was found. 
Blood or serum of human beings and monkeys taken 
after the administration of sulfanilamide or prontosil 
was found by Colebrook et al. (27) to have a bacterio-
static or bactericidal action against hemolytic 
streptococci greatly in excess of anything encountered 
in normal blood or serum. Fuller (48 ) claims that 
prontosil as such has little or no streptococcal-
killing power, but that the bactericidal action is 
derived from the sulfanilamide, a reduction product 
of pront,9sil. Bliss anctLong ( IG also found para-
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aminobenzenesulphonam.ide to be the active bacterio~ 
static substance. 
Experimental work by Long and Bliss (I6,I7,I5,'4,73 
77 ), revealed a greater bacteriostatic action on 
one of the hemolytic streptococci than on the other 
two. The difference beirween the Ellis on one hand and 
C203 and Schw on the other was observed repeatedly. 
The mode of action was of utmost concern, for strept-
oco ccic multiplication was inhibited by the chemical 
but in addition it was felt that the streptococci must 
have been damaged to permit such a marked degree of 
phagocytism( 74) • Capsular formation however, as 
suggested earlier by Levaditi and Vaisman was not 
found. Although explanation of the exact mechanism of 
action on the streptococci is impossible, it is import-
ant to note, that the change brought about by sulfan-
ilamide therapy was not instantaneous, see fig. 3. 
llrs. (, ,. ,,_ t' 7 
Fig. 3. Growth curve stra n Ellis in normal 
ho~se serum broth, & in normal horse serum broth con-
ta:2,fn1ng sul.fanllamide. 
MODE OF ACTION 
A period of several hours was required before the 
change began to develop. This suggested the poss-
ibility of a union between the organism and chem-
ical by which a marked change in the metabolism 
of the streptococcus was brought about ( 77). In-
hibition of growth and phagocytosis of the organ-
isms occurred 6 to 8 hours after the administration 
of the chemotherapeutic agent, indicating that there 
may have been some change in the organism or chemical 
substance,73). Buttle et al. (24) rurwever, demonstrated 
a slight bactericidal effect for sulfanilamide in 
whole blood invitro, but in deleucocyted blood there 
seemed to be no difference in diminution of rate of 
growth; a point against, direct action on the bacteria. 
It is also extremely difficult to rule out the bact-
ericidal effect of serum from patients with hemolytic 
streptococcus infection' 3!). 
Finkelstein-Sayliss et al. (4!) found that sulfanil-
amide was highly soluble in fats and they felt that 
it was very likely concentrated in the fatty envelope 
of the streptococcus. Experimental work seemed to 
bear out their contentions. The results show that the 
streptococci pollulate very rapidly in the presence of 
sulfanilamide; when the peak of growth is reached the 
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population falls away extremely fast, see fig. 4 .. 
With increasing age of the cultures this rise and fall 
becomes progressively less pronounced and in the 26 
hour strain, the organisms are almost immediately 
susceptible to the bactericidal action of sulfanil-
am1de. the young forms took up more fat than the 
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Fig. 4. fable & Graph showing the effect of 
sulfanilamide over a period of 24 hours; first 
stimulation and then depressionof growth. 
older culture. Two explanations were offered: {I) that 
with the diminution of the percen~age of fat as age 
increases, the concentration of sulfanilamide in the 
fat of each individual cell or organism increases, 
and this increase is responsible for the bacteriostatlc 
action upon the older cultures; or (2) that sulfan11-
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amide acts first as a stimulant and secondarily as 
a depressant. 
In spite of the vast amount of work that has been 
done to ellicit the mechanism whereby sulfan1lam1de 
produces the desired clinical results, it still 
remains a mystery. Barron and Jacobs { 9) found 
that prontylin had a slight inhibiting effect on the 
oxidation of glucose by the hemolytic streptococcus, 
however the conditions under which this was done are 
not given. Bigler et al. (I4) claims the action 1s 
independent of the leucocytes; Gross, Cooper, and 
Peebles (53) also disagree with Long and Bliss, for 
they found no stimulation of phagocytotis as described. 
According to Gross et al. " the degree of protection 
observed in splenectomized mice was identical with that 
obtained in the normal animals. 11 Therefore one may 
conclude that the reticulo-endothelial system plays 
a very minor, 11r any, role in producing clinical results. 
Thus far very little if any effect on the heAolyt1c 
activity of the staphylococcus and streptococcus hemo-
toxin has been observed (54). Green ( 5~ presented a 
theory of the activity of Comgo Red ( a sulfanilamide 
derivative), in which he feels that the activity is due 
to its electro-nei:r8.t1ve properties and that invading 
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bacteria c~ng positive charges are electrically 
rendered harmless. This is as yet purely theoretical 
and has no definite proof. 
Perhaps one of the most recent attempts to secure 
information. as to the mechanism of action of sulfan-
ilamide upon the streptococcus was made by Warren, 
Street, and Stokinger ( I2~, who measured the effect 
of this drug upon the oxidation-reduction potentials 
of the hemolytic streptococcus. It was found that 
sulfanilamide caused an elevation of the 0-R potential. 
The means whereby this deviation was produced remains 
at present obscure. 
Although many more experiments no:t;Jhentioned, 
might be included to argue for ndirect action on the 
bacteria •1 , we shall turn our attention to the 
second theory. 
Sulfanilamide, ODlt Ancillary to the Operation 
£!_ the Cellular e ense MechanISm of the Body: 
As was mentioned earlier in the chapter Domagk (36 ) 
believed that prontosil was conjugated with the infect-
ive agent but later stimulated phagocytosis. Mellon 
and Bambas ( 9Q however, were convinced that. other factors 
aided in the destruction of bacteria. Experimentally 
they were able to show that tlb.e;almost negligible effect 
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of sulfanilamide on minute streptococcus 1nnocula, 
3 to 6 organisms, might under appropriate conditions 
be amplified to an extent reminiscent of the human 
voiee's intensification by a loud speaker. Incred-
ible as it may seem, this effect was brought about 
by employing "physiological" or normal salien instead 
of broth in the ordinary routine of diluting the 
streptococci to the minute innocala, so necessary for 
the quantitative bacteriostatic test. A I5 to 30 
minute exposure to salien had an inhibitory effect (90) 
but it was so slight, as ordinarily to be considered 
negligible. 
Yet this apparently negligible effect lasting only 
a few hours became a critical one when "potentiated" 
by dilutions of at least I:I00,000 sulfanilamide, in 
the presence of normal serum • .Mathematically, the 
situation 1s one where I plus 2 plus 3, instead of 
adding up to 6, comes to.66 or conceivabl' 666~ This 
is what is meant by the use of the term: 11potent1ationn 
a phenomenon well known to pharmacologists. Acting 
alone none of these factors would be capable of 
accomplishing the aesirect bacteriostatic result; but 
acting to-gether, their effect is multiplied, so that 
a critical end result is produced ---- in this instance 
-33-
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complete inhibition of bacterial growth {90). 
Subtended is a representative table 11lustrating 
the situation (see fig. 5). 
Diluent Medium Cone. o:r No. of Hours 
Sulf anilamide Coccr-seeded 6------24 
Broth Broth 0 4 IOOO 0 .. " I:4,ooo 5 500 0 .. t1 I:I0,000 5 500 0 
ti Serum 
" (undiluted) O 5 IOOO 0 H " I:4,000 6 500 0 
NaCl " I:I0,000 3 IOOO 0 
ti 0 .85% Broth 0 I8 400 IOOO 
It H 1:4,000 0 50 400 
II " I:I0,000 0 200 500 fl Serum 
fl (undiluted) O 8 50 IOOO 
" " I:4,ooo 0 0 0 II 11 I:I0,000 0 0 0' •, 
Fig.5. This table presents some of the experimental 
evidence supporting Mellon and Bambas' theory of 
"potentiation". 
Buttle et al. (24) confirmed Mellon and Bambas theory, 
that the primary mechanism was one of mutual reciproca-
tion between sulfanilamide and the bacteriostatic powers 
of the host. This was demonstrated in de-leucocyted 
blood or culture medium, in which a definite diminution 
in the rate of growth did not appear. 
Osgood Cro) maintains that eulfan1lam1de itself did 
not kill the organisms but rendered them vulnerable to 
bactericidal substances present in the normal serum, 
probably by preventing the formation, or by neutral-
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ization, of toxins or aggreseins of the organisms. He 
claimed that culture of human marrow makes possibae 
a type of control not attainable in animal experi-
mentation or in clinical investigation. Much exper-
imental evidence (Iob supports the view that bacter-
icidal substances must be present in the serum of the 
animal, be developed, or be introduced from another 
source if sulfan1lamide is to save lives. As yet it 
is not known, whether this action on the toxins or 
aggressins may be due to the destruction o! some 
substances necessary for their formation, to a direct 
action on the organism preventing the formation of 
toxins or aggressins, to the destruction of nascent 
toxins or aggressins, to their destruction after 
formation, to catolysis of a.n anti-toxin ---- toxin 
reaction, or to a sufficiently slow rate of production 
so that they are destroyed by the natural processes 
of oxidation as rapidly as they are formed. It has 
been found that sulfanilamide does not affect the 
dehydrogenasee of the pneumococcus (S9), therefore 
any inhibitory action which the drug produces must 
be by augmenting the body defenses. 
Branham and Rosenthal. (19 ) demonstrated better 
therapeutic resul.,ts when using com-binat1ons o~ serum 
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and drug. A synergistic action seemed to exist, since 
the increased effectiveness of combined therapy was 
greater than the additive effects of the drug.and 
serum alone. 
Finkelatein and Birkeland (40 ) in an attempt to 
analyze the significance of the various factors which 
aight play a part found; (I) that when leucocytes were 
well washed with plasma (2) that when leucocytes were 
treated with varying dilutions of the drug and then 
well washed (3) that when streptococci were treated 
with varying concentrations of the drug and then washed, 
no more phagocytosis occurred than in the controls. 
It appears that serum or a factor in it is necessary 
to obtain the effect of the drug. The phagocytoais of 
hemolytic streptococcus was enhanced in vitro but fresh 
serum or plasma appeared to be necessary for completion 
of the reaction. Not only did these drugs increase the 
number of bacteria phagocytosed per leucocyte but also 
the number of leucocytes taking part in the reaction 
(99 ). Just how sulfanilamide enhances phagocytosis 
is not clear, but our results (40 ) briefly reported 
here (see fig. 6) suggest that sulfanilam1de or a 
serum-sulfanilamide complex acts as an opsonin. 
If sulfanila.m±de is a strept-oeoecic anti-toxin, 
-36-
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it would not be unreasonable to expect it to behave 
much like anti-toxins. This was shown· by Kemp ( 65) 
in attempting to neutralize streptococcus toxin with 
dilutions as high as I:I,000. Neutralization did not 
occur, neither could any anti-hemolytic quality be 
exhibited. 
Dil. or Drug No. of Cocci % of leucooytes 
.. ~1ocytosed laking part 
I:I,000 192 20 % 
I:I0,000 246 32 % 
I:S0,000 5!4 60 % 
I: I00,000 296 48 ·~ 
!:250,000 82 12 % 
Control 96 I6 % 
Fig. ~~ The effects of var7B:g dilutions of 
sulfanilamide on the phagocytosis of hemolytic 
streptococcus. 
· Locke et al. ( 72) emphasized the "fitness rating" 
as an index of condition and capacity for resistance. 
Rabbits with high fitness ratings accomplish the 
removal of intravenously injected pneumococci from 
the blood more rapidly than rabbits with lower ratings. 
Treatment with sulfanilam1de and especially and espec-
ially with sulfanilamide plus fitness-promoting adju-
vant tends to keep the blood stream clear eno~h of 
pneumococci invading from the infected focci, to permit 
the natural defensive forces to get an upper hand. 




vides a tissue environment in which the cocci are 
unable to multiply freely and to invade adjacent 
tissues as well as the blood stream. Kolmer (69) 
likewise agrees that sulfanilamide apparently restrains 
the growth of beta hemolytic streptococcl and thereby 
facilitate their phagocytosis. 
Negative results have been obtained by McKinley 
et al. (86) in treating experimental virus infections. 
One of the essential differences between virus and 
bacterial infections is that the former are invariably 
of an intra-cellular nature while the latter are chiefly 
inter-cellular, though in some bacterial diseases cell-
ular invasion is also characteristic. It is suggested 
that sulfanilamide is unable to exert its action ( ?---
~-bacteriostatic, virustatic or what-not ) against the 
infecting agent when it has invaded the tissue cells 
as in the case of virus infections. The efficacy of 
sulfanilamide in specific bacterial diseases may depend 
partly on its successful attack against ext~cellular 
organisms, while the host cells themselves are contri-
buting to the defense against the invading microbes. 
On the other hand, we may assume from present evidence 
that viruses find conditions within the tissue-cells 
favorable, rather than unfavo.Pable, for survival and 
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multiplications. 
Summarizing the various theories, which have been 
mentioned in this chapter we find that the "mode of 
actionu is still a mystery. Bell (II) concludes that 
inhibition of bacterial division occt.rs in vitro and 
in vivo. This effect is enhanced by serum and tissue 
cells. Degenerative changes 1n the organisms are incon-
stant and do not influence virulence or toxin produc-
tion on even the first sub-culture. The toxins remain 
but seem incapable, in the presence of sulfan1larnide, 
of destroying cells except in infections more massive 
than those encountered clinically. The type of cell-
ular response remains dependent on the host; is not 
in itself drug-conditioned. Phagocytosis is enhanced 
indirectly through bacteriostaSis b•t is not related 
to drug action on body cells, although opson&n produc-
tion appears to be hastened under drug-altered condi-
tions. Host supremacy is ultimately dependent on biol-
ogic response to the invader. The drug seems to 
inhibit the multiplication and spread of bacteria and 
protects cells from the destructive influences of 
infective organisms, thereby inducing a more favorable 
environment for opsonin production and the action of 




Realizing the impossibility of summarizing the 
.el:tl.liaal results of sulfanilamide. since its discovery; 
I have attempted to review the literature of 1938 and 
use, the summary of Bel.ion, Gross, and Cooper ( 93) for 
a review of the clinical results prior to 1938. 
" ?he diverse clinical manifestations- caused by the 
hemolytic streptococcus, regardless of the organs affect-
ed, or the severity of the attack, have yielded to the 
S"!_lfonamide compounds in a uniformly sat1sf actory 
fashion. Not only has the mortality been convincingly 
reduced in its more malign manifestations, but in those 
more difficult to assess with this sole critetf.on, the 
course and complications of the diseases have been 
profoundly modified. 
Meningitis, with a mortality approaching IOO per 
cent, puerperal sepsis, with its 25 per cent mortality 
and cellulitis with sepsis----to say nothing of 
peritonitis-----all have responded to these compounds 
in an impressive manner. The reduction of meningitis 
mortality in a fair sized series of cases to approx-
imately 15 per cent is in itself arresting; but when 
this is often associated with a prompt sterilization 
of the spinal fluid under oral a&nini strati on of the 
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drug, the results are nothing short of dramatic. And 
while scarlet fever has not been critically studied 
as yet, it appears that its course and complications 
have been favorably affected. 
or note too have eeen the results 1n erysipelas · 
where a total of I,000 cases had a mortality rate of 
less than one per cent. Moreover, the all important 
age factor has been invoked as a criterion in the study 
of a sizable number of these cases. Observed aide by 
side with a series having the most approved alternate 
form of treatment (antitoxin and ultraviolet radiation) 
the verdict definitely favor•d the sulfonamide com-
pounds. 
Conditions of lesser severity such as tonsillitis, 
cystitis, pyelitis, mastoiditis, and lymphangitis, 
have evoked uniformly favorable responses. And in cer-
tain mixed infections where the streptococcus plays 
an important role, such as Ludwig's angina and gas 
gangrene, the advance reports, while not sufficient 
1n number to reach a conclusion, have been sufficiently 
favorable to justify further tr1a1.• 
These authors continue their summary (93) -----
"About 80 percent of I4I cases of gonorrhea treated 
with sulfanilamide hav~ been reported cured. These 
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patients, however, have not been followed sufficiently 
long to allow conclusions regarding the permanence of 
the cures. 
Although only 12 cases of men1ngococcal meningitis 
have been treated with sulfonamide compounds, the 
percemtage of cures (91.7) 1s impressive; and for the 
same reason the single report of II cases of Type III. 
pneumococcal pneumonia is arresting. 
Infections of the urinary tract caused by E.coli 
and in some cases by staphylococci have been reported as 
cured in about 75 per cent of over ISO cases. The find-
ings of renal irritation or of clear-cut nephritis 
have been reported in more than IS cases in which this 
condition was secondary to erysipelas or other hemo-
lytic streptococcal infections. For the most part 
all signs of the complications disappeared under 
sulfonamide therapy. 
The few favorable reports of gas gangrene, certain 
skin diseases, and of quartan malaria await confirmatory 
evidence of larger numbers of cases. 
Difficult of evaluation or distinctly unfavorable 
are the reports dealing with typhoid and undulant 
fever, non-hemolytic streptococcal infections, i~ect­
ious arthr1t1s, Hodgkin's disease, fil~tasis, and 
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other conditions of unknown etiology." 
An at.tempt was made to summarize the clinical 
results of sulfanilamide therapy during I938,by 
tabulating all the cases reported. I found however, 
that such an attempt was futile; for,many of the journals 
were foreign, some were not being subscribed for by 
our 11bBary, and others were either being bound or in 
use. Therefore the results, as listed in this table, a.Be 
at best very meager. It has been included to give the 
Disease 




Ludwig's Ansina (strept.) 
Meningitis (gonorrheal) 







Paratyphoid ttB'' Carrier 
Peritonitis (pneumococeic) 
Poliomyelitis (in monkeys)--no 
Pneumonia 
Various Infections 








































reader an idea, as to the effectiveness of the drug 




Toxic symptoms usually develop following large 
doses of a drug or 1n those individuals, who are 
extremely sensitive to it. Sulfan1lamide is no 
exception. Vertigo, hyperventilation, nausea,anorexia, 
dermatitis, cyanosis, aggranulocytosis, anemia and 
aulph. & methemoglob1nemia were the most consistent 
symptoms (57). ihese symptoms are usually accompanied 
by drowsiness, irritability, and very evident mental 
confusion involving principally false perception, 
difficulty in 9oncentration and slow response to 
questioning. Recovery from the subjective symptoms 
in the normal subjects is not complete for forty-eight 
hours. Most symptoms usually disappear rather promptly 
after the administration of the drug is discontinued. 
In the discussion of the individual toxic symptoms, 
the more frequent ones shall be considered first. 
CYAN OS IS 
Cyanosis, frequently observed in patients receiving 
sufan11amide therapy, seems to be almost generally 
attributed to sulfhemoglobinem1a or methemoglobinemia. 
Few writers, however, have actually identified these 
derivatives in cyanotic patients. Ches1ey (25) reported 
eight cases showing cyanosis after sulfanilamide therapy, 
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1n which sulfhemoglob1nem1a and methemoglob1nem1a were 
ruled out. .Mull and Smith 65) were also unable to 
demonstrate methemoglob1nem1a and sulfhemoglobinemia 
by spectroscopic examination. 
Marshall and Walzl ( 84 ) admit that sulfhemoglobin 
as well as methemoglobin may occur under certain oond-
i tlons after administration of sulfan1lamide, but it 
seems clear that these abnormal iron pigments supply 
by no means the only and probably not the main, explan-
ation of the cyanosis so frequently encountered in 
using this drug. 
Payne ([Olf) believes that methemoglob1nem1a is an 
important factor 1n producing cyanos1s, but he has 
found the gray discoloration of mucous membranes and 
skin persists in both humans and dogs long after 
methhemoglobin and sulfhemoglobin have disappeared 
from the blood. It is possible that this residual 
discoloration may be explained by the presence of 
small amounts of paraphenol 1n the blood and tissues 
especially since accwnulations of a foreign brown 
pigment may be observed by microscopic examination: 




Marshall et al. quoted by Otten berg (102) , have 
demonstrated that the respiratory function of the 
hemoglobin is unaltered. Methemoglobin and sulfhemo~:. 
globin have been found in some cases but in amounts 
far too small to explain the intense cyanosis. Otten-
berg (I02) states that whole blood whether arterial 
or venous, has a chocolate brownish tinge. Al though 
aerated gains oxygen 1n normal amounts, it does not 
become bright red but remains dark. This led Otten-
berg to seek for a derivative of sulfanilamide in the 
erythrocytes. He and his co-workers were able to 
reproduce the phenomenon in vitro by use of ultra-violet 
light. This they believed might offer an explanation 
for cranosis in vitro but remains questionable in vivo. 
King and Leslie ( 67 ) found no instances of 
anoxemia, nor any 1n which the oxygen saturation was 
low enough to explain the relatively marked cyanosis. 
These observations tend to indicate that diminished 
oxygen saturation of the arterial blood does not play 
a significant role 1n cyanosis. This is 1n keeping with 
the clinical observation that the administration of 
oxygen fails to relieve cyanosis. Mull and Smith ( 95 ) 
however found an actual lowering of the capacity of the 
blood for oxygen and they belie•ed oxygen was indicated 
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as well as something to increase the capacity of the 
blood for taking up oxygen. 
CEREBRAL MANIFES'rATIONS 
Long et al. ( 7~ list dizziness, nausea and headache 
among the common cerebral t.oxic effects. These manifest-
ations hav.e seldom been severe enough in ward patients 
to warrant discontinuing administration of the drug. In 
ambulatory patients these symptoms may constitute a 
serious problem. Alcohol is contra-indicated during 
sulfanilamide therapy as it tends to accentuate the 
cerebral toxic manifestations. Patients who are receiving 
sulfanilamide should be warned against driving automobiles, 
because tho dizziness and decreased mental acuity some-
times seen may render them dangerous on the road. 
FEVER 
Simple fever unaccompanied by other toxic manifest-
ations occurs frequently. Occasionally the question 
of :C_d:ifferentlating the drug fever from fever caused by 
some infection, causes difficulty. Long and Bliss ( 7~ 
regard a simple fever, a fairly common toxic manifestation 
in the course of sulfanila.mide therapy. The question 
of whether one may resume treatment with the drug after 
the fever has disappeared is of importance. A test dose 
( 5 grains) to patients who have previously had a febrile 





response is noted within twelve hours 1t is unwise to 
continue the drug. 
Hageman and Blake ( 55) during a study of a series 
of cases treated with sulfan1lam1de, t'c:nmd, th.at'.·a 
characteristic febrile reaction was encountered in a 
fair proportion of the cases. The similarity between 
drug fever and serum sickness was rather striking. The 
time interval, the fever and the rash are characteristics 
common to the two. Since the reaction occurs after the 
drug has been decreased in dosage or even discontinued 
suggests that it is not the immediate concentration of 
sulfanilamide 1n the oo¢y at the time of the reaction 
which 1s responsible for the drug fever but rather 
that sulfanilamide itself or in a combined or changed 
form is antigenic. 'l'hus far attempts to :throw light 
on the mechanism of the reaction have failed. 
ACIDOSIS 
Acidosis 1s the condition in which acids are 
absorbed or formed in excess of their elimination or 
neutralization, or in which there is an excessive 
loss of bases from the body ( 26) • 
Southworth ( II1) 1n a series of fifty cases was 
ab1e to show two with clinical acidosis. Therefore a 
series of fifteen consecutive prontyin-treated patients 
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were studied. Every single case ~howed some fall 1n 
the C02 combining power of the blood plasma. It 1s 
generally conceded that the co2 combining power may 
be Slightly·lowered as long as the temperature is 
elevated but no specific studies of streptococcal 
infections are recorded. In one case, the patient, when 
afebrile and suffering from no streptococcal infection, 
the C02 combining power fell from 59.8 volumes per cent 
to 37.2 volumes per cent after the ingestion of 6.9 gm. 
ot prontylin. 
Many physicians advise taking sodium bicarbonate 
with sulfan1lam1de to prevent acidosis; sodium lactate 
however has been found to be more desirable for it 
produees less gastric disturbance• 
Hartman et al. {57) consider the question of 
acidosis entirely on a physiological basis. When the 
reduction of the base bicarbonate in the serum has o 
reached the level at which, despite the decrease in 
carbonic acid brought about by the lll.yper-ventilation, 
the ratio of the bicarbonate ; carbonic acid has again 
reached the normal value of 20 : I, then there is no 
further need to excrete bicarbonate into the urine, 
and the latter may again become normally acid. At this 
time, the pH of. the blood should be lower than it was 
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when bicarbonate was being excreted 1n excessive amounts, 
and the data confirms this expectation. The co2 content 
of the serum at this same time would still be reduced 
because both the bicarbonate and carbonic acid levels 
are below normal. It is easily conceivable that with 
this existing bicarbonate deficit, a true acidosis 
might develop, should ketosis, lactic, or other acid 
accumulations occur; or, on the other hand, should the 
pyperventilation suddenly cease, allowing carbonic acid 
to accumulate. 
DERMATITIS 
Sulfanilam1de therapy may result in several distinct 
types of dermatoses, but before entering into a dis-
cussion of the distinct types, a description of the 
dermatitis will be given. The eruption is distributed 
over the face, occipital portion of the scalp, neck, 
shoulders and arms downward to the mid-portion of the 
backs of the fingers ( 5I ) . The lesions are more 
numerous on the extensor aspects of the arms than on 
the flexor surfaces. On the face the outlines of the 
individual lesions are only faintly discernible because 
their borders had fused into one another to form a;._ 
diffuse and patchy erythematous process. The eruption 
stopped at the aairl1ne in front and on the sides but 
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was continuous below with the lesion on the neck. Its 
outstanding characteristic was its limitation to the 
regions of the skin, which had been exposed to di~ect 
sunlight ( 46 ) • The affected zones were clearly set 
of~ from the normal skin by the line of clothing at 
the "vtt of the neck, by sleeves rolled up to the elbows 
or in the region of the ankles. The hands are fre-
quently swollen out of proportion to the degree of 
symptoms that existed elsewhere. 
Newman and Sharlit {98)'found that if patients re-
ceiving sulf anilamide were exposed to direct sunlight 
for five hours, an eruption of the skin developed with-
in twelve hours after the exposure. The eruptions 
were similar and characteristic. They consisted of 
numerous scattered, irregularly grouped macular plaques, 
varying in size from that of a pea to that of the palm 
of the hand. As the lesions progressed, they became more 
confluent. The color was a deep red with a violaceous 
tinge, the exact hue is aptly described as maroon. 
Moderate itching accompanied the dermatitis but scaling 
was not present. Frank ( 46 ) offered the suggestion 
that heliosensitivity created by the drug or some of its 
chemical reactions with hemoglobin might play a part 
in this type of toxic reaction. Thie would help account 
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for the infrequency of this type of toxic manifestation 
in the numerous cases reported, because the patients 
have been predominately hospitalized. 
Schwentker and Gelman (II~ found the entire body 
surface usually affected, but in some cases was limited 
to the buttocks or the legs. The mucous membranes are 
apparently unaffected and the lesions seldom p~oduce 
severe 1tcb.1ng. The rash develops very rapidly without 
prodromal symptoms in most cases. 
Summarizing~ the reported clinical findings (42,II2,79 
94, & 96 ), we find that sultanilamide therapy may result 
1n several distinct types. of toxic dermatoses ( I2I). 
The first and most common type is precipitated by expo-
sure to sunlight. In this type the level of suifanila-
m1de 1n the blood is not abnormally high, nor is there 
ordinarily a sensitivity to the drug. However, the 
combination of factors occurring internally, such as 
disease processes: .and the irritative effects of the 
sun's rays, results in the occurrence of a localized 
dermatitis which may be complicated by areas of derma-
titis at distant points. 
The second t7pe of dermatitis is that ln''.Wh1ch' 
definite sensitivity to the drug occurs,·resultlng m--
a *eneit1.zat1on dermatitis~ The~pat1ent:can not 
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tolerate further .sulfanilamide 1n any dose. 
The third type of dermatitis is that resulting from 
poor toleration of, or saturation with, sulfan11am1de 
and presenting the typical picture of toxic dermatosis. 
It is, therefore,important that the clinician be 
able to differentiate these three types of dermatitis, 
and there-by be able to institute the proper therapeutic 
measures. 
AflGl:WWLOCYTOSIS 
Past experiences with drugs synthesized on a benzene 
base prompted predictions of toxic manifestations invol-
ving the hematopietic tissues, and this theoretical 
prognosis has been borne out 1n practice ( I3). Kracke, 
quoted by Young (I28), presented evidence that aggranulo-
cytosis might be caused by amido-pyrene, phenacetin, 
certain gold salts and arsphenamine. These drugs pessess 
1n common the benzene ring with an attached NH2, or 
amine group, which increases the ease of oxidation. A 
consideration of the formula of sulfa.nilamide suggested 
the possibl1ty that this drug might also be capable of 
producing aggranulocytosis. 
Allen and Short ( 3 ) .have tabulated the eight cases 
of aggranulocytosis caused by sulfanilamide ( see fig.8). 
Sulfhemoglob1nem1a, acute hemolytic anemia, and 
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leucopenia have shown improvement on discontinuation 
of the drug. Granulocytopenia, however might make its 
appearance even after cessation of therapy(I28) • 
a.s,. A_'ft!' "'Se) A~.,"" 't ... u .... ti~ . f· B.e. dl ~ 4- 'Ri'fs tDe4ths /lo. .f n .... ,. 13e on ~" ~ ..• J..Dr ,. 
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Fig. 8. Tabulation of cases of aggra.nulocytosis 
caused by sulf'an1lam1de, listed b7 Alien $nd f)bort(3 ). 
Domagk, quoted by Bresgen ( 20), claims that repeated 
small doses over a long period of time will eventually 
lead to an exhaustion of the marrow cavities and result 
1n leukopenia and aggranulocytosis. Larger doses over t 
shorter intervals are -considered most desirable. Jennings 
and Southwell-Sander (64 ) found it impossible to state 
the exact amount of sulfanilamide needed to produce 
aggranulocyto•~s. In thttr case the size of the dose 
appeared to be the important factor. As soon as immature 
erythrocytes or a leucopen1a appears, therapy should 
cease immediately. 




changes consistent with aggranulocytosis. The myeloid 
series of the marrow showed maturation arrest with 
stem cell hyperplasia and absence of more mature cells. 
There was reduction in the nucleated red blood cells 
and many degenerate forms----consistent with secondary 
anemia. ~hey believe from these observations that 
sulfanilamide exerts a toxic effect on both the red and 
white blood cells. 
Bigler et al. { I4 ) attempted to determine the 
leukocyte response to sulfan1lam1de therapy by making 
daily counts before, during and after administration of 
the drug. In no instance was an increase in the leucocyte 
count found. They did believe, however, that the drug 
caused a depression of leucocytes, not only because of 
instances of leucopenia but because of the spectacularly 
rapid fall in leucocytes at the end of an infection, 
which is often followed by a moderate rise in leucocytes 
after the drug is discontinued. The alteration in the 
leucocyte response was in the nature of a marked absolute 
reduction of all the cell elements without an;. character-
istic relative change. The granulocytes were not reduced 
out of proportion to the other cells, and at no time 
were toxic changes demonstrated. The Schilling differen-




a healing infection. 
McGuire ( 85) demonstrated a rapid decline in the 
total white count of a pat!ent given sulfanilamide, 
after having recovered from a leukopen1a developed 
two months before.· Whitby ( I2~ found that after cess-
ation of the drug, the hemoglobin and leucocyte count 
returned to normal (see fig. J'•). He believes that 
---------•"' 
o r ,o ,, .20 
Fig.9. Graph shows the 
course of recovery of hemo-
globin and leucocyte count 
1n a patient who had been 
given a continuous daily 
course or 3gm. for four 
months. 
Do.ys 
dangerous aggranulocytosis is undoubtedly due to 
idiosyncarsy, in the same way as with amidopyrine; 
particular care being necessary with debilitated patients. 
Blood examinations however do not always forecast a 
sudden disaster, therefore one must wa~ch for clinical 
signs as well. 
ANEMIA 
fhe anemic condition usually develops rather rapidly. 
There may be sudden"'masa1ve hemolys1s as indicated by 
an accompanying icterus, a rapid drop in hemoglobin, 
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and the appearance of urobilinogen in the urine (107). 
At the same time the patient appears very toxic and ill, 
although there may be little or no fever. The blood 
count shows marked anemia, with evidence of regenera~ion, 
both in the red and white cell series. Large numbers 
of immature cells may present a clinical picture of 
leukemia. 
The mechanism of the producti'on of these anemias is 
as yet unknown, but it does not seem to be of the nature 
of a true idiosyncrasy (72 ). It is probable that the 
anemias represent an abnormal susceptibility on the part 
of the red blood cells of certain individuals to severe 
hemolysis by sulfanilamide. 
Harvey and Janeway ( 58) reported three cases of 
severe anemia but were unable to prove that sulfanilamide 
was responsible for the rapid hemolysis. They ruled out 
hemolytic jaundice, sickle-cell anemia and paroxysmal 
hemoglobinuria, but their attempt to reproduce the 
clinical picture met with failure. Careful blood studies 
revealed no significant changes. In a case, reported 
by Wood (127), the hemolytic streptococcus was considered 
a factor 1n producing hemolys1s; however the clinical 





The resemblance of these hemolytic anemias to the 
hemolytic crises produced by the use of phenyl-
hydrazine is quite striking (58 ). It is possible that 
these individuals produce from the sulfanilamide a 
small amount of the toxic product having an action like 
phen7lbydrazine or produce such a substance much more 
rapidly than the average patient. !herefore with the 
possibility of an acute hemolytic anemia in mind, blood 
counts should be taken at regular intervals, to note 
the initial changes of the blood picture. The drug there-
by being with drawn previous to the symptoms. 
SULFBEMOGLOBINEMIA AND METHE»OGLOBINEMIA 
Sulfhemoglobinemia is formed in vivo and becomes 
dangerous if the total hemoglobin falls below thirty 
perceeilt. As mentioned under the heading o:t"CYANOSIS!' 
sulfhemoglobinemia frequently accompanies cyanosis, 
although it is not considered the essential factor in 
producing cyanosis. According to Archer and Discombe 
( 6 ), hydrogen sulphide is constantly being absorbed 
from the large gut; being formed therein by the action 
of bacteria on food residues, or as a result of the 
administration of elementary sulfur, which is known to 
be absorbed partly as a sulfide. This absorbed hydrogen 




the plasma and partly excreted by the lungs. If a 
grossly excessive a.mount of HZ3 is formed, or if a 
normal amount of H~S is formed, when a catalyst for 
2 
the combination of hemoglobin with H2S is present 1n 
the blood, some of the sulfide will combine with the 
hemoglobin in the erythrocyte; and since this cell, 
which has a: .. 11fe of several weeks, is not lysed, will 
1n the course of time develop a detectable sulfhemo-
globinemia. The time which will elapse before sulfhemo-
globin is detected will depend upon the a.mount of H28 
absorbed from the gut, on the nature and quality of the 
catalyst administered, and the detection of sulfhemo~ 
globin. 
There are two possible causes of sulfhemoglobinemia; 
namely, idiosyncrasy and overdose. A normal dose is an 
overdose to a sensitive patient( 47). 
Pa.ton and Eaton ( IO~ have found that the adminis-
tration of Jig 804 simultaneously with, or within two 
or three days preceding sulf an1lam1de gives rise in 
most persons, to sulfhemoglobinemia. In the absence of 
sulphates, large doses are well tolerated. Archer and 
Discombe ( 6 ) provide the following explanation of 
KgS04 increasing sulfhemoglob1nemia------"Magnes1um 
sulphate breaks down into magnesium and sulphate ions; 
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the magnesium ions form an insoluble material and 
increase the osmotic pressure of the gut contents 
so that the body fluids pass to the gut lumen. The 
more liquid contents of the colon form an admirable 
medium for bacterial growth; further, by the action 
of purges the absorption of food is decreased, and 
more passes to the colon unabsorbed. Since many 
bacteria normally present in the colon split cystine 
to hydrogen sulphide, an increased production of 
hydrogen sulphide may be expected. Therefore any 
treatment which helps the formation of liquid stool 
may be expected to accelerate the formation of 
sulfhemoglobin. 
Bensley arid Ross ( I2 ) found methemoglo~inemia 
to be present with relatively small doses as well as 
large doses of sulfan1lam1de. They found that it 
usually disappears after the drug is discontinued. 
Stoness CII9) likewise reports a case, in which the 
patient became cyanotic after the second day of 
sulfanilam1de administration. After the drug was 
stopped the methemoglobin disappeared. 
Cyanosis due to methemoglobin disappeared ver1 
rapidly (after cessation of the dl:'ug), while sulfhemo-
globinem1a was much more persistent (Io3 ) • Oxygen 
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relieves methemoglobinemia, whereas nothing helps 
sulfhemoglobinemia; methemoglobinemia passed off 
in twenty-four hours and sulfhemoglobin is 
eliminated by the liver 1n six weeks. 
'l'OXIC NECROSIS OF THE LIVER 
Massell and jones-( ) reported one case of 
toxic necrosis of the liver following the use of 
sulfanilamide. The patient, a white male, 37 yrs. 
of age was treated for a gonorrheal infection. 
After receiving 500 grains, he developed a headache 
and felt weak. His urine became dark, amber colored; 
and he developed a fever and rash. The drug was 
discontinued with the appearance of toxic manifestations. 
Six weeks later, the patient noticed a tear at the 
urethral meatus, and on his own volition without 
seeking advice, took fifteen grains of sulfanilamide. 
Within five hours he developed a rash; three days later 
he became jaundicea, the urine appeared dark and the 
stools were gray. At that time there was no anemia or 
hepatomegaly. The patient left the hospital, against 
oraers; only to be readmitted one week later with the 
clinical and laboratory picture of acute toxic necrosis 
of the liver. The patient was deeply jaundiced, anorexic 




tmgers.:.be,low the costal margin. After one week he 
developed some urinary suppresion coinciding with a c· 
high N.P.N. retention. Intravenous glucose was given 
1n repeated doses and the patient responded favorably. 
TOXIC OPTIC NEURITIS 
This condition does not seem to occur often but will 
be included here to serve as a reminder of the pessible 
toxic effects, manifested by sulfanilamide. 
Bucy ( 23) reported a case of optic neuritis, which · 
apparently developed as a result of the aruuinistration 
of sulfanilamide. The drug was given on three occasions 
----the first two; headache, cyanosis, diarrhea and a 
choking sensation developed. On the third, there was a 
severe loss of vi•ion due to toxic optic neuritis 
following 0.3 gram of sulfan1lam1de. 
A brief tabulation of ti1e complications of sulfanil-
amide in a series or two-hundred nases has been appended 
bJ Fitzgibb6n'r and: Silver ( ), see fig.IO on next page. 
In conclusion let it be borne in mind that this 
chemotherapeutic agent has many toxic effects, and beeaase 
of them the patient should be carefully supervised while 
sulfanilamide is being administered. This supervision 
should consist of careful clinical abservations, frequent 
and regular temperature recordings, a daily hemoglobin 
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determination and a daily total white blood cell 
count. If these procedures are adhered to as a routine, 
the toxic manifestations of sulfanilamide will be 
noted in their inception. 
Symptom Ho. of Points I Percentaf e Comment • of poin s 
Weakness 72 36 most frequent 
Dizziness 67 33 
Dyspnea 60 30 
Headache 33 I6.5 
Anorexia 32 I6 
Drunk feeling 25 12.5 
Sleepiness 22 II 
General aching I9 9.5 
Cyanosis I9 9.5 0 tent for 2 one patient 
Vomiting 9 4.5 
Fever 8 4 
Ra.sh II 6.5 50% photo-sens. 
Constipation 6 3 
Diarrhea 2 I 
Paresthesia 4 2 
Cycloplegia (temp.) O 0.5 
Peri. neuritis 0 0 
Pre-cordial Pain 2 I One case known 
outside this series 
Temporary 4eafness 2 0.5 
Urticaria I 0.5 
Toxic necrosis of Liver I 0.5 One case reported 
Death 0 0 
Fig.IO. Incidence of s14e-react1ons in 200 consecutive 
cases of gonorrhea being treated with sulfan1lamide. 
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The development of sulfa.nilamide therapy, which 
at present occupies the attention of the medical 
profession all ever the world, is now being extended 
to new compounds derived from the original prontosil 
and sulfanilamide. 
The original prontosil was a water-insoluble basic 
azo-dye (sulfamido-chrysoidin) suitable for oral 
administration only, and for the purposes of parenteral 
therapy the sodium salt of an acid dye ( disodium 4-
sulfamidophenyl-2-azo-7-acetylamino-I-bydroynaphthalene 
3, 6-disulfonate) had to be evolved. It was found by 
a series of clinical investigations that, when used 
early, it was a remarkable remedy for the cure of 
erysipelas and to be helpful in treating puerperal 
fever and certain other hemolytic infections. 
As a result of studies by Fourneau and his coworkers 
at the Pasteur Institue in Paris, it was soon found that 
this complex dyestuff owed much of its virtue to the 
fact that it was evidently reduced in the body to the 
simpler compound, p-aminobenzenesulfonamide, and that 
this relatively easily prepared compound was equally 
eff eoti ve in experimental inf actions { I ) • 'rhis 
discovery provided investigators with a simple and 
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easily accessible material which has been studied 
extensively from all aspects, and much work baa been 
devoted to modifying and improving this parent sub-
stance with the object of increasing its efficiency, 
widening the range of bacterial diseases which can 
be influenced, and reducing its toxic but rarely fatal 
effects. Although thousands of such compounds have 
been synthesized, hundreds have been tried exper1ment-
all7 1n animals, and a dozen or more have been used 
clinically, few have come into practical use. 
Whitby ( I2!j bas classif'ied those compounds which 
have exerted interest, or which have been found worthy 
of clinical trial, into the following groups: 
I. Those in which substitution has been made 
in the amino group: sulfamido-cbr7so1d1n; prontosil 
soluble; benz¥1am1nobenzenesulfonam1de (Prosepta-
zine) ; and loluseptazine. 
2. Those in which one hydrogen atom of the 
sulfonam1do group bas been substitued: Uleron; 
2-(p-am1nobenzenesulfonam1do) pyridine (Dagenan); 
4, 4 1 -diam1no benzenesulfonanllide; 4-amino-4' -
dimetbylaminobenzenesulfonanilide; and 4,3'..;d1a.m1-
nobenzenesulfonan111de. 
3. Compounds of the sulfone type which are chemi-
cally unrelated to the sulonam1dea: 4,4'-acetamido-
diphenylsulfone; and 4,4'-d1aminod1phenylsulfone. 
In the first group, including sulfonamide itself, 
there is activity against hemolytic streptococci of 
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groups A, Band c, but not D and F, meningococei and 
gonococci, but none against the pneumococci with the 
exception of type III, which is itself virtually a 
streptococcus. Toxicity and solubility are altered, 
rather than efficiency or range. Multiplication of 
sulfonamide groups tends to extinguish activity. In 
the second group the range of activity 1n most has 
been increased to include at least pneumococcus, and 
they possess an equal if not greater activity against 
bacteria affected by the first group. Out-standingly, 
the best member of this group is 2-(p-amino-benzene-
sulfonamido) pyridine, (2-sulfanilyl-am1nopyr1dine). 
With regard to the sulfones, the range of activity is 
again extended to include pneumococcus, and efficiency 
against hemolytic streptococcus is increased; but 
toxicity has rendered many of them unsuitable for clin-
ical trial although the di-(p-acetylaminophenyl) 
sulfone has been successfully introduced as a well-
tolerated remedy against streptococeic, gonococcic, 
and pneumococc1c diseases, and the sulf'one "Prom1n11 
has been shown to be of great value 1n the treatment 
of exper1menta1 infections in animals. 
In order to shorten this paper, only two of the 
more popular derivatives w111 be included in this 
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discussion, namely: Neoprontosil and Sulfapyridine. 
Neorrontosll 
eoprontosil is disodium 4-sulf amido-phenyl-2-
azo-7 -acetylamino-I-hydroxynaphthalene 3,6-disulfonate. 
It occurs in the form 
of a dark red, tasteless, 
odorless powaer, soluble 
in water, but virtually 
insoluble in organic solvents. 
Neopronosil is well adapted for peroral use by reason 
of its somewhat su~erior efficiency (I09, 8) and rela-
tively greater therapeutic margin of safety by this method 
of administration as comps.red with parenteral adminis-
tration. According to Barlow (8 ), the minimum lethal 
dose of Neoprontosil, when administered by mouth cannot 
be accurately determined in mice due to high tolerance 
and limited gastric capacity o# the animals. However it 
exceeds 40gm. per kilo of body weight as compared with 
the minimUIIJ lethal dose of 6.25 gm. per kilo of sulfa-
nilamide administered orally. 
Raiziss et al. (I04, in a comparative study of four 
sulfonamide compounds, determined that neoprontos11 
exerts almost the same therapeutic effect by mouth as 
doea.sulfanila.mide.. Of 30 mice 1n1'ected with a virulent 
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culture of beta-hemolytic streptococci, treated daily 
with IO mg. of sulfanilamide by mouth. 77 per cent 
were protected for seven days, and 66 2/3 per cent for 
twenty-eight days. Of a corresponding group of mice 
similarly infected, but treated with IO mg. of Neo-
prontosil daily by mouth, 77 per cent were protected 
for seven days and 63 per cent for twenty-eight days. 
Barlow ( 8 ) pointed out that the minimum protective 
dose varies directly with the virulence of the culture. 
The theory that the activity of N,eoprontos11 is 
due solely to the sulfanilamide liberated through reduc-
tion in the body is not universally accepted. 
An increasing number of investigators incline to 
the view that the different components of the complex 
Neoprontosil molecule contribute to its specific effect. 
Brown and Bannick ( 22) have felt for some time that 
the relation of Neoprontos11 to sulfanilamide is pecul-
iar and not clearly defined. If, as has been sug@ested, 
Neoprontosil is tffective only in direct proportion to 
the sulfanilamide released, it is difficult and puzzl-
ing to understand the excellent results obtained with 
from 40 to IOOc.c. of Neoprontosil 2.5 per cent solution 
(containing in IOOc.c. only II grains or 0.73 Gm. of 
sulfanilam1de). As these ~.uthors state, the conclusion 
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seems inevitable that unless one wished to attribute 
such satisfactory results to the small amount of 
sulfanilamide, it must be assumed that Neoprontosil 
is capable of producing other added chemotherapeutic 
actions in the body. 
Gross, Cooper and Lewis ( 54 ) and their coworkers 
presented data to show that Neoprontosil----but not 
sulfanilamide-- showed significant ne•traliz~ng power. 
This property consists in the ability of the drug to 
inhibit hemolysis of hemolytic streptococci. 
King, Henschel and Green ( 66 ) also reported that 
colonies 1n culture mediums containing I:IOOO Neopron-
tosil are surrounded by smaller zones of lysis, 1n re-
lation to their size, than in control sets, indicating 
that the amount of hemolysin available for erythrocyte 
destruction is moderately reduced. 
'lolerance 
Carefully conducted clinical investigations have 
demonstrated that side effects are less frequently 
observed and are generally less severe after Neoprontosil 
than after sulfanilamide. Herrel and Brown ( 6I ) recent-
ly stated that the "accumulated experimental and 
clinical evidence also tends to indicate that the tox-
1c1ty of' Neoprontosil is comparatively low. This low 
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toxicity of Neoprontos11 1S particularly impressive 
when comparison is made with the toxicity of sulta-
nilamide." Many of the patients who were intolerant 
to sulf an1lam1de were successfully treated by these 
authors at the Kayo Clinic with Neoprontosil (oral). 
A number of the pat.ients showed leukopenia; as the 
physicians were unwilling to administer sulfan1lam1de 
tor fear of further depressing the leukocyte count, 
N.eoprontosil ( oral) was substituted, with the result 
that the white count returned to normal. Furthermore, 
the compound was administered orally in two cases of 
cholangitis and in one case of jaundice without any 
evidence of increased hepatic injury. 
Bannick, Bro·wn and Foster ( 7 ) observed only 
I5.4 per cent of reactions in 96 cases. They remarked 
that untoward symptoms, when they occurred, were 
generally mild. Slight fatigue and vertigo were noted 
in several eases. Mild symptoms of gastro-intestinal 
irritability appeared within the rirst day of treatment, 
though these were subsequently avoided by giving the 
drug an hour before meal time. In four cases, nausea, 
vomiting and cramps led to discontinuance of the drug. 
Cyanosia, insufficient to hinder treatment, was detected 
1n four cases. Only one patient became acutely ill from 
-70-
DERIVATIVES OF SULFANILAMIDE 
the drug. This patient suffered chills, fever and vomit-
ing. However, recovery was immediate oft.discontinuance 
of treatment. A number of patients who were unable to 
tolerate sulfanilamide were successfully treated with 
Neoprontosil ( oral ) without experiencing untoward effectll 
It must be remembered however, that patients having a 
sensitivity or idiosyncrasy to the preparation may exper-
ience side effects similar to those which have been re-
ported with sulfanilamide (see chapter on "TOXICOLOGY"). 
Clinical Considerations 
In a report. by Bennick, Brown and B'-oster ( 7 ) of 
the Mayo Clinic concerning the use of Neoprontosil (oral) 
in 96 cases, including I2 cases of ulcerative colitis, 
the patients ranged 1n age from I3 to 83 years. The 
average total dose in the course of treatment was 26.5 
Gm., while the largest dose received by any patient was 
90 Gm. !he duration of the traatment was, on the average, 
about seven days, the longest course extending over a 
period of twenty-five days. These authors recommend the 
administration of Neoprontosil one hour before meals, 
since gastro-intestinal symptoms, though usually mild, . 
were relieved by giving the drug when the stomach was 
relatively empty. Slight fatigue and vertigo, occasion-
ally noted, did not constitute a severe annoyance. As 
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has been stated, no evidence of renal irritation was 
revealed by urine analysis. The patients were informed, 
however, that the urine and occasionally the stools 
would be discolored red. In most instances where counts 
and morpllological examination of the blood cells and 
hemoglobin estimations revealed changes, these could be 
considered as associated with the primary disease. 
There was pronounced improvement in each of the nine 
cases which were uncomplicated.by othe~ disease. 
In a later paper Brown, Herrell and Bargen { 21 ) 
presented further observations on the clinical use of 
Neoprontosil alone in chronic ulcerative colitis. Eight 
cases were treated in all. In each case there was marked 
improvement within a few months. The results obtained 
in a few cases reported in this series led them to con-
clude that early cases with mild to moderate involvement 
of the bowel offered the best opportunity for this type 
of therapy. Naturally, when the disease has existed for 
some time with resultant anatomic deformity of the bowel 
and changes in the physiologic function with its attend-
ing manifestations, a chemotherapeutic agent directed 
against the infective process may hardly be expected to 
be entirely effective. 
Using Neoprontosil in those infections which have 
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been shown to be responsive to sulfan1lam1de, Herrell 
and Brown (61) treated approximately 150 patients 
suffering from infections due to the hemolytic strep-
tococcus, pneumonia caused by the pneumococcus in which 
specific serum was not available, chronic ulcerative 
colitis, cholangitis, osteomyel1tis, cutaneous manifest-
ations, such as lupus erythematosus, pemphigus, etc., 
as well as other infections caused by organisms which 
have not responded satisfactorily to sulfanilamide. 
Although the result of the therapy in each individual 
case was not reported, these authors felt that in 
general " they seemed to justify the opinion that the 
therapeutic influence of Neoprontos11 (oral) approxi-
mates to a condiderable extent that exerted by sulfanil-
amide." In infections caused by organisms which have 
failed to respond to sulfanilamide, successful results 
were naturally not obtained with Neoprontosil ( oral ). 
Dr. Josephine B.Neal ( 97 ) of the New York City 
Department of Health refers to the peroral administration 
of Neoprontosil • She found that that in treating such 
bacterial diseases, particularly meningitis, which re"' 
spond to sulfanilamide compounds, the use of Neopron-
tosil orally was followed by rapid and remarkable improve-
ment. In<the event the patient could not swallow or retain 
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medication by mouth, Neoprontosil was administered 
parenterally. Occasionally, it was given intraspin-
ally with similar results. 
SULFAPYRIDINE 
The research for chemical substances active against 
bacteria led to surveys of compounds effective against 
the pneumococcus but although, from time to time, 
substances more active than sulfanila.mide were discover-
ed, most had the dis~dvantage of being relatively toxic. 
Yfhi tby (125), on May 1938, was able to report that 
the compound 2-(p-aminobenzenesulfonamido)pyridine, 
now widely known as sulfapyridine, is chemotherapeut-
ically active in experimental infections 1n mice against 
pnewnococc1 of types I,II,III,V,VII,VIII, and especially 
against types I, vu: and VIII, and that moeover, the 
compound had promise of being efficient in the treatment 
of experimental hemolytic streptococcus and meningococous 
infections in mice. Successful therapy has also been 
reported in regard to meningococcal ( 34), gonococcal(IO,, 
72 ) , staphylococcal ( 29), and streptococcal (45 ) 
infections. 
Biochemical and B1o1ogical Data 
Sul:fapyr1d'Iiie ( "i&B.693";-"Dagenan") was one of 46 
new compounds prepared by A.J.Ewins and M.A.Ph111pps 
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1n the chemical research laboratories of May & Baker, 
Ltd., at Dagenham, Essex, England, in a search for a 
substaanee witll a sufficient degreeof activity against 
the pneumococcus to justify its use in the treatment 
of acute lobar pneumonia { I). 
"Dagenan" is a white, or nearly white, powder 
melting at I90.5-I9I.5 degrees c. and having a slightly 
bitter taste. It is soluble in water to the extent of 
0.28 Gm. in IOOOc.c. at Z7 degrees c. and is sparingly 
soluble in the the usual organic solvents. It has both 
acid and basic properties and is therefore soluble in 
acids, forming stable solutions below a pH of 4. Due to 
the activity of the SOZfH2 hydrogen it is also soluble 
1n alkalies, forming solutions with a pH of IO to II, 
(see structural formula given below). 
11,/to -/-HN-
The drug, ;,which has· been called' by Yarlous na.mes ... --
sulfan1lam1de~pyridine, sulfone-pyrid1ne, pyridine 
sulfanilamide compound, dagenan, M&B 693, finally was 
named sulfapyr1dine by the Council on Pharmacy and 
Chemistry ( 32) • 
Evans and Gaisford (38 ) recommend the following 
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dosage; I-3 months ---- 0.8 ~- daily 6-24 .. I.5 " .. 
3 yr. 2.0 ti " 
___ ....... 
5 ff 3.0 " ti ------
Mac Coll ( 78) reports the use or sulfapyridine in 
33 children. The most successful results were obtained 
1n 13 pneumococeal infections. All the patients showed 
marked improvement with1n 48 hrs., regardless of the 
day of the disease on which treatment was begun. Temper-
atures usually reached normal in 20 to 48 hours with an 
average of 36 hours. The true crisis of lobar pneumonia 
was not seen but, rather, a rapid lysis. In general , 
the course of the pneumocoocic patient was one of marked 
improvement during the first da.JI with relief of malaise, 
and some fall in temperature. During the second day the 
appejiite improved. Resolution usually began with the 
fall in temperature. 
Toxic effects such as vomiting, cyanosis, methemo-
globin formation, and a fall in hemoglobin during 
treatment have been noted and indicate that the same 
caution must be employed as with the use of sulfanil-
am1de. 
Long et al. (74 ), on the basis or the experimen~al 
and clinical evidence available prior to February 1939 
concluded that car~ful therapeutic trials of the effects 
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of sulfapyridine in pneumococcic, severe staphylococcie 
and Friedla.nder's bacillar infections seemed waranted. 
but that good evidence was not at hand that the drug is 
as effective as, or superior to, sulfanilamide in the 
treatment of hemolytic streptococcus, meningococcus, 
gonococcus or Welch bacillus infections. 
Mode of Action 
---- ~he main theories advanced for the action of the 
sulfonamide drugs 1n bacterial in~ections postulate 
stimulating action on the body defenses; neutralization 
of toxic bacterial products; action on the bacteria as 
germicides, or by interference with invasive power and 
ability to multiply rapidly; and the combinations of 
these actions. 
Fleming { 44 ) believes there is simple inhibition 
of growth (and possibly of toxin production) and while 
the organisms growth is stopped and its vitality lower-
ed, some a.gent 1n·:.t.ae body damages the capsule or 
perhaps causes autolysis. The &load serum is thought to 
contain the active principle. He believed that the bac-
teria were rendered more susceptible to phagocytosis 
by the polymorphonuclear leukocytes and the monocytes. 
This conception agreed perfect1y with that of Long and 
his coworkers ( 74 ) but was somewhat in opposition to 
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the conclusions of Whitby (I25 ) • 
It is probable that the efficacy of sulfapyridine 
depends on its ability to inhibit the growth of the 
pneumococcus---irrespective of type---and it has been 
suggested that the drug interferes with the mechanism 
whereby the cocci utilize serum proteins as foodstuffs. 
Recovery presumably depends, however, on the patients 
ability to develop specific antibodies to neutralize 
the pneumococcus carbohydrate substance_ and cause a 
degradation of the infecting organisms ( I ) • 
Bacterial Chemotherapy 
"This rational explanation that the sulfonamide 
drugs are not simple germicides, but probably act by 
neutralization of some metabolic function or enzymic 
activity, awaits a complete solution through the 
labors of a bacterial chemist. It has already been 
noted that, though both sulfanilamide and sulfapyridine 
are equally effective in blocking the vital food for 
streptococcus, the latter is decidedly more effective 
in blocking :Cbat for pneumococcus. Rosenthal ( 108 ) 
once suggested that ultimately we may be able to 
devise a specific cb.emotb.erapeutic agent for each. t9pe 
of bacterial infection and, eventually, for the various 
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virus diseases. With the present theory of specific 
interference with food assimilation, or with some 
factor essential for multiplication, the hope for an 
antibacterial chemotherapy based on sulfur compounds 
may be fulfilled since that--in the sulfanilamides, 
their derivatives, homologs and analogs--organic chem-
istry can provide the biochemical and clinical worker 
with compounds 1n infinite variety. The possible defense 
available to bacteria against a specific drug of the 
sulf an1lamide type would be the development of resist-
ant strains for, as Hans Zinsser has remarked, 'though 
actually complex in function and metabolism, these 
supposedly simple things ( the bacteria, protozoa, and 
viruses) display an amazing biological and chemical 
flexibility, and the phenomena of infection constitute 
an accelerated evolution extraordinarily favorable for 
the observation of adaptive changes.' To combat this 
evolutionary defnse shift a suitable change in the 
chemical constitution of the drug might be all-necessary 
and essential. Whatever the future may bring, so much 
has been accomplished 1n the four short years since the 
introduction of the sulfanilamides that the future is 
bright with hope in the battle against the bacterial 
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